BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology. 2018;155:1128-1139.e6. [PMID: 29981779 DOI: 10.1053/j.gastro.2018.06.079] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Demirtas CO, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, Alahdab YO, Ozdogan OC. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:517-523. [PMID: 31524775 DOI: 10.1097/MEG.0000000000001528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology 2019;156:1215-7. [DOI: 10.1053/j.gastro.2018.09.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Isfordink CJ, Maan R, de Man RA, van Erpecum KJ, van der Meer AJ. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection? Eur J Intern Med 2021:S0953-6205(21)00296-X. [PMID: 34563447 DOI: 10.1016/j.ejim.2021.08.023] [Reference Citation Analysis]
4 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
5 Cao P, Jin Q, Feng L, Li H, Qin G, Zhou G. Emerging roles and potential clinical applications of noncoding RNAs in hepatocellular carcinoma. Semin Cancer Biol 2020:S1044-579X(20)30191-7. [PMID: 32931952 DOI: 10.1016/j.semcancer.2020.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Singal AG, Patibandla S, Obi J, Fullington H, Parikh ND, Yopp AC, Marrero JA. Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1925-1932.e1. [PMID: 32920214 DOI: 10.1016/j.cgh.2020.09.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Singal AG, Murphy CC. Hepatocellular Carcinoma Surveillance: An Effective But Complex Process. Gastroenterology 2019;156:1215. [PMID: 30543799 DOI: 10.1053/j.gastro.2018.08.066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kuo SC, Lin CN, Lin YJ, Chen WY, Hwang JS, Wang JD. Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. JAMA Netw Open 2021;4:e2114680. [PMID: 34165580 DOI: 10.1001/jamanetworkopen.2021.14680] [Reference Citation Analysis]
9 Serper M, Kaplan DE, Shults J, Reese PP, Beste LA, Taddei TH, Werner RM. Quality Measures, All-Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis. Hepatology 2019;70:2062-74. [PMID: 31107967 DOI: 10.1002/hep.30779] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
10 Ding Y, Sun Z, Zhang S, Zhou L, Xu Q, Zhou D, Li Y, Han X, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma. Dis Markers 2020;2020:8879944. [PMID: 33062075 DOI: 10.1155/2020/8879944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
12 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
13 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
14 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Reference Citation Analysis]
15 Raffetti E, Portolani N, Molfino S, Mentasti S, Baiocchi GL, Magoni M, Donato F. Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s. Clin Res Hepatol Gastroenterol 2021;45:101433. [PMID: 32409284 DOI: 10.1016/j.clinre.2020.04.004] [Reference Citation Analysis]
16 Jasirwan COM, Hasan I, Sulaiman AS, Lesmana CRA, Kurniawan J, Kalista KF, Nababan SH, Gani RA. Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia. Curr Probl Cancer 2020;44:100480. [PMID: 31130257 DOI: 10.1016/j.currproblcancer.2019.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Majeed A, Roberts SK, Kemp W. RE: No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology 2019;156:1217. [DOI: 10.1053/j.gastro.2018.09.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
19 Yuan M, Wang Y, Sun Q, Liu S, Xian S, Dai F, Zhang L, Fan Y, Wang F, Yang D, Zheng Y, Deng Z, Tan W, Liu Y, Cheng Y. Identification of a Nine Immune-Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma. Biomed Res Int 2021;2021:9798231. [PMID: 33506049 DOI: 10.1155/2021/9798231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
21 Schauer C, van Rijnsoever M, Gane E. Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand. J Viral Hepat 2019;26:1372-6. [PMID: 31323163 DOI: 10.1111/jvh.13179] [Reference Citation Analysis]
22 Hernandez-Meza G, Vietti Violi N, Said D, Novogrodsky E, Villavisanis D, Maron SZ, Frere J, Schiano TD, Friedman S, Boffetta P, Branch A, Taouli B. MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. Abdom Radiol (NY) 2021;46:5142-51. [PMID: 34283266 DOI: 10.1007/s00261-021-03212-7] [Reference Citation Analysis]
23 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol 2019;54:1027-32. [PMID: 31389730 DOI: 10.1080/00365521.2019.1649454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
24 Jepsen P, West J. We need stronger evidence for (or against) hepatocellular carcinoma surveillance. J Hepatol 2021;74:1234-9. [PMID: 33465402 DOI: 10.1016/j.jhep.2020.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
26 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Loosen SH, Castoldi M, Jördens MS, Roy S, Vucur M, Kandler J, Hammerich L, Mohr R, Tacke F, Ulmer TF, Neumann UP, Luedde T, Roderburg C. Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC. PLoS One 2021;16:e0247917. [PMID: 33711036 DOI: 10.1371/journal.pone.0247917] [Reference Citation Analysis]
28 Ladhani S, Ohri A, Wong RJ. Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors. Journal of Clinical Gastroenterology 2020;54:218-26. [DOI: 10.1097/mcg.0000000000001313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
30 Qian X, Yan X, Zhai X, Li N, Qu C, Lu F. Hepatocellular Carcinoma Surveillance and Treatment: A Way to Reduce Cancer-related Mortality in Cirrhotic Patients. J Clin Transl Hepatol 2019;7:1-2. [PMID: 30944811 DOI: 10.14218/JCTH.2019.00002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Delaney LJ, Tantawi M, Wessner CE, Machado P, Forsberg F, Lyshchik A, O'Kane P, Liu JB, Civan J, Tan A, Anton K, Shaw CM, Eisenbrey JR. Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences. Ultrasound Med Biol 2021;47:2523-31. [PMID: 34130880 DOI: 10.1016/j.ultrasmedbio.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Choi DT, Kum HC, Park S, Ohsfeldt RL, Shen Y, Parikh ND, Singal AG. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2019;17:976-987.e4. [PMID: 30616961 DOI: 10.1016/j.cgh.2018.10.031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
33 Bates SE, Kelley MJ. VA Cancer Research: A Legacy and A Future. Seminars in Oncology 2019;46:305-7. [DOI: 10.1053/j.seminoncol.2019.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Chen VL, Singal AG, Tapper EB, Parikh ND. Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. Liver Int 2020;40:947-55. [PMID: 31943689 DOI: 10.1111/liv.14379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
35 Hu H, Xu L, Luo SJ, Xiang T, Chen Y, Cao ZR, Zhang YJ, Mo Z, Wang Y, Meng DF, Yu L, Lin LZ, Zhang SJ. Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in Hepatocellular Carcinoma. Int J Med Sci 2020;17:1897-908. [PMID: 32788868 DOI: 10.7150/ijms.46091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Liu J, Tang W, Budhu A, Forgues M, Hernandez MO, Candia J, Kim Y, Bowman ED, Ambs S, Zhao Y, Tran B, Wu X, Koh C, Surana P, Liang TJ, Guarnera M, Mann D, Rajaure M, Greten TF, Wang Z, Yu H, Wang XW. A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma.Cell. 2020;182:317-328.e10. [PMID: 32526205 DOI: 10.1016/j.cell.2020.05.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
37 De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F, Ricke J, Paprottka P, Friess H, Werner J, Gerbes AL, Mayerle J, Engel J. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 2020;69:168-76. [PMID: 30878947 DOI: 10.1136/gutjnl-2018-318193] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
38 Lang S, Martin A, Kasper P, Schramm C, Kütting F, Goeser T, Steffen HM, Demir M. Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scand J Gastroenterol 2020;55:222-7. [PMID: 31990240 DOI: 10.1080/00365521.2020.1718747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Tayob N, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, White DL, Davila J, Kanwal F, El-Serag HB. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2020;. [PMID: 32768590 DOI: 10.1016/j.cgh.2020.07.065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
41 Gil-Gómez A, Rojas Á, Liu CH, Gallego-Duran R, Muñoz-Hernandez R, Fassina G, Pontisso P, Ampuero J, Romero-Gómez M. Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World J Gastroenterol 2021; 27(48): 8343-8356 [DOI: 10.3748/wjg.v27.i48.8343] [Reference Citation Analysis]
42 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 147] [Article Influence: 131.0] [Reference Citation Analysis]
43 Su F, Weiss NS, Beste LA, Moon AM, Jin GY, Green P, Berry K, Ioannou GN. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. J Hepatol 2021;74:850-9. [PMID: 33245934 DOI: 10.1016/j.jhep.2020.11.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
44 Cooper GS. Should We Abandon Current Hepatocellular Carcinoma Screening Practices? Gastroenterology 2018;155:972-4. [DOI: 10.1053/j.gastro.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
45 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
46 Zhao C, Xing F, Yeo YH, Jin M, Le R, Le M, Jin M, Henry L, Cheung R, Nguyen MH. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:406-19. [PMID: 31490419 DOI: 10.1097/MEG.0000000000001523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
47 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
50 Demirtas CO, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:882-888. [PMID: 32395972 DOI: 10.1097/MEG.0000000000001685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Wang J, Huang R, Huang Y, Chen Y, Chen F. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis. Adv Ther 2021;38:3342-61. [PMID: 34014550 DOI: 10.1007/s12325-021-01762-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Biselli M, Garuti F, Neri A. Hepatocellular carcinoma surveillance: an open question. Hepatobiliary Surg Nutr 2019;8:431-2. [PMID: 31489324 DOI: 10.21037/hbsn.2019.02.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Song JH, Goh MJ, Park Y, Oh JH, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. Scand J Gastroenterol 2021;56:274-80. [PMID: 33399022 DOI: 10.1080/00365521.2020.1866063] [Reference Citation Analysis]
54 Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer 2020;19:77. [PMID: 32295598 DOI: 10.1186/s12943-020-01188-4] [Cited by in Crossref: 62] [Cited by in F6Publishing: 73] [Article Influence: 31.0] [Reference Citation Analysis]
55 Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci 2019;76:4203-19. [PMID: 31300868 DOI: 10.1007/s00018-019-03215-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]